

**ביוליין אר אקס בע"מ  
("החברה")**

תאריך: 27.10.2011

לכבוד  
הבורסה לניירות ערך בתל אביב בע"מ  
באמצעות המגנ"א

לכבוד  
רשות ניירות ערך  
באמצעות המגנ"א

**הנדון: הבהרה לעניין אישור בעלות באסיפות**

בהמשך לזימוני אסיפת בעלי מניות ואסיפת מחזיקי כתבי האופציה (סדרה 2) של החברה מיום 27.9.2011, מובהר בזאת כי "אישור בדבר בעלות בכתבי האופציה (סדרה 2)" משמע לרבות יפוי כוח מהחברה לרישומים.

בכבוד רב,  
ביוליין אר אקס בע"מ

---

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

*For the month of October, 2011*

---

**BioLineRx Ltd.**

(Translation of Registrant's name into English)

---

**P.O. Box 45158  
19 Hartum Street  
Jerusalem 91450, Israel**

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:      **Form 20-F** ☒      **Form 40-F** ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:      **Yes** ☐      **No** ☒

---

Further to the Registrant's Current Report on Form 6-K dated September 26, 2011 announcing the conveneing of Special General Meetings of its Shareholders and holders of its Series II Options on November 2, 2011, the Registrant wishes to make the following clarification to the Company's shareholders:

Proof of ownership of Series II Option holders who hold Series II Options through members of the Tel-Aviv Stock Exchange, may include a power of attorney provided by the nominee company of the Registrant at the Tel-Aviv Stock Exchange (Hevra Le-Rishumim of Bank Leumi Le-Israel Ltd.).

This report on Form 6-K is being incorporated by reference into all effective registration statements filed by us under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioLineRx Ltd.**

By: /s/ Philip Serlin

Philip Serlin

Chief Financial Officer and Operating Officer

Dated: October 27, 2011